Latest Asx Company Filings News

Trek Metals has accelerated its exploration at the Christmas Creek Project with expanded drilling revealing promising high-grade gold mineralisation and a newly discovered gold nugget field. Backed by a $3.5 million capital raise and government co-funding, the company is poised for further breakthroughs.

Stealth Group Holdings reports a robust $6 million in pre-sales for iPhone 17 accessories, marking a 50% increase from last year and signaling strong momentum ahead of the global launch.

Anatara Lifesciences has received nearly $1 million from the Australian Government’s R&D tax incentive, providing a vital capital injection to advance its Anti-Obesity pre-clinical studies.

Arovella Therapeutics reported a robust $20.9 million cash position as it prepares for its first-in-human trial of ALA-101 and expands its solid tumour pipeline through new licensing agreements and leadership appointments.

Bubs Australia has appointed Joe Coote as its new CEO, bringing extensive international FMCG and dairy leadership to spearhead its global growth ambitions in infant nutrition.

Brightstar Resources secures backing from major Aurumin shareholders and option holders for its proposed acquisition, pending expert approval and absence of superior offers.

International Graphite Limited (ASX – IG6) has had its trading suspension lifted following the announcement of a new agreement to develop a graphite processing facility in Europe.

Peninsula Energy has completed a major reset of its uranium offtake contracts, terminating five of six agreements with a $6.6 million payout, while advancing commissioning of its Central Processing Plant toward first yellowcake production in Q3 2025.

Compumedics has secured two significant four-year distribution agreements in China worth A$24.4 million, reinforcing its strategic foothold in Asia with committed annual growth of at least 10%.

Emyria has secured a landmark multi-year funding agreement with Medibank to reimburse PTSD patients under its Empax program, alongside opening a second clinic and reporting durable clinical improvements in treatment-resistant PTSD cases.

Bubs Australia Limited reports a strong FY25 with 29% revenue growth to $102.5 million, positive EBITDA turnaround, and sustained cash flow improvements. The company also advances its US market ambitions with a key FDA submission underway.

SQX Resources has advanced its exploration strategy by integrating new and historical data at its Queensland projects, aiming to define a mineral resource while maintaining a solid cash position.